Apolipoprotein aiv as an antidiabetic peptide
AssigneeUniversity of Cincinnati
InventorsPatrick Tso, Sean Davidson, Stephen Woods, Fei Wang
Life of this patent
Estimating the term…
Abstract
Methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus are disclosed. The methods include administering an effective amount of apolipoprotein A-IV to the subject. The pharmaceutical composition includes apolipoprotein A-IV formulated for administration to a subject for the treatment of type two diabetes mellitus. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject in need thereof.
Claims24
A method for treating type II diabetes mellitus in a subject in need thereof, the method comprising administering to the subject an effective amount of an apolipoprotein A-IV or a biologically active analogue thereof having at least 90% identity to the apolipoprotein A-IV.
A method of lowering blood glucose level in a subject in need thereof. the method comprising administering to the subject an effective amount of an apolipoprotein A-IV protein or a biologically active analogue thereof having at least 90% identity to the apolipoprotein A-IV.
A method for substantially restoring glucose tolerance in a subject in need thereof to a normal level, the method comprising administering to the subject an effective amount of apolipoprotein A-IV or a biologically active analogue thereof having at least 90% identity to the apolipoprotein A-IV.
A pharmaceutical composition comprising the apolipoprotein A-IV or biologically active analogue thereof having at least 90% identity to the apolipoprotein A-IV formulated for administration to a subject for the treatment of type II diabetes mellitus.
Dependencies are inferred from the claim text.